

Index

A

- ABCB19, mitoferrin I stabilization, 124
- Acute chest syndrome. *See* Sickle cell anemia
- Acute splenic sequestration crisis. *See* Sickle cell anemia
- ADA. *See* Adenosine deaminase
- Adair, Gilbert, 2
- Adenosine deaminase (ADA), gene therapy for
 - deficiency, 356–357
- AGM. *See* Aorta-gonad-mesonephros
- AHSP. *See* α -Hemoglobin stabilizing protein
- ALAS. *See* Aminolevulinate synthase
- α -Globin
 - comparative biology. *See* Hemoglobin
 - mutations. *See* α -Thalassemia
 - normal variants of gene cluster, 187
 - structure and expression of gene cluster, 184–187
 - unstable variants, 392–393
- α -Hemoglobin stabilizing protein (AHSP),
 - β -thalassemia pathophysiology, 200
- α -Thalassemia
 - epidemiology, 246–247, 285–286
 - gene defects of α -globin gene cluster
 - α -^{ZF} mutation, 192
 - deletions in duplicated structural genes, 189–191
 - duplications, 188
 - large deletions beyond gene cluster, 191–192
 - normal variants versus pathological variants, 187–188
 - overview, 183–184
 - translocations, 188
 - upstream regulatory element
 - competition for elements, 193–195
 - deletions, 193
 - geographic distribution, 139
 - hemoglobin E interactions, 230–231
 - hemoglobin H disease. *See also* Hemoglobin Bart's hydrops fetalis syndrome
 - diagnosis, 249–251
 - laboratory screening, 249–251
 - management, 251
 - severity, 247–249
 - malaria natural selection effect on distribution, 153–154
 - management
 - iron chelation therapy
 - costs, 280–281
 - deferasirox, 279
 - deferiprone, 279–280
 - deferoxamine, 277–279
 - initiation, 275–276
 - monitoring, 275, 277, 280
 - principles, 271–272
 - mental retardation syndromes
 - ATR-16 syndrome
 - chromosomal abnormalities, 257–258
 - genetic defects, 256
 - ATR-X syndrome
 - ATR^X identification and characterization, 261–264
 - clinical features, 259–260
 - genotype–phenotype correlation, 262–263
 - hematology, 260–261
 - severity, 263
 - X-linked heredity, 261
 - overview, 138, 255–256
 - mild forms, 247
 - molecular diagnosis, 291
 - myelodysplastic syndrome association. *See* α -Thalassemia-myelodysplasia, 138
 - overview, 137, 245–246
 - phenotypes, 184
 - prevention programs
 - genetic counseling, 293
 - population control, 286–287
 - preimplantation diagnosis, 294–295
 - prenatal diagnosis, 293–295
 - prospects, 296
 - sickle cell anemia severity impact, 307
- α -Thalassemia-myelodysplasia (ATMDS)
 - ATR^X mutations, 266
 - overview, 138, 264–265
- Aminolevulinate synthase (ALAS)
 - ALAS-2 mutation
 - X-linked protoporphyria, 127
 - X-linked sideroblastic anemia, 124, 127–128
 - heme synthesis, 116–117
 - isozymes, 117
 - regulation, 121–122
- Anemia. *See* Iron deficiency anemia; Sickle cell anemia; X-linked sideroblastic anemia
- Aorta-gonad-mesonephros (AGM), erythropoiesis, 15–17
- Aspirin, β -thalassemia intermedia management, 223

Index

- Atherosclerosis, hemoglobin as disease modifier, 410–411
- ATMDS. *See* α -Thalassemia-myelodysplasia
- ATR-16 syndrome
- chromosomal abnormalities, 257–258
 - genetic defects, 256
 - overview, 191–192
- ATRX*
- ATR-X syndrome genotype–phenotype correlation, 262–263
 - characteristics of gene and protein, 261–262
 - protein function, 263–264
 - α -thalassemia-myelodysplasia mutations, 266
- ATR-X syndrome
- ATRX* identification and characterization, 261–264
 - clinical features, 259–260
 - genotype–phenotype correlation, 262–263
 - hematology, 260–261
 - severity, 263
 - X-linked heredity, 261
- 5-Azacytidine, hemoglobin F induction, 90, 97
- B**
- BCL11A
- hemoglobin F induction studies, 91–94, 96–97
 - hemoglobin gene expression regulation, 61, 68, 75–77
 - polymorphisms and β -thalassemia impact, 203–204
- β -Globin
- comparative biology. *See* Hemoglobin mutations. *See* β -Thalassemia
 - unstable variants, 392–393
- β -Thalassemia. *See also* Hemoglobin E β -thalassemia
- classification, 213
 - clinical presentation
 - anemia, 205–206
 - hemoglobin E β -thalassemia, 200–201
 - heterozygous disease, 199–200
 - homozygous disease, 200
 - iron overload manifestations
 - bone effects, 208
 - cardiac manifestations, 206–207
 - endocrine dysfunction, 207
 - hepatic manifestations, 207–208
 - overview, 204–205
 - tissue measurement, 206
 - epidemiology, 285–286
 - gene therapy
 - clinical trials, 361–363
 - erythroid cell models, 361
 - immunodeficiency disease management, 355–357
 - mouse models, 360–361
 - overview, 240, 355
 - selective amplification in vivo, 361
 - transduction optimization, 364–365
 - vectors
 - gammaretroviral vectors, 358–359
 - lentiviral vectors, 359–360
 - limitations, 356–357
 - locus control region, 358–359
 - retroviral vector modification for safety, 357–358
 - genetic modifiers, 201–204
 - geographic distribution, 139
 - hematopoietic stem cell transplantation
 - adults, 345
 - alternative donors, 345–346
 - mixed chimerism, 347
 - outcomes
 - haploidentical donors, 346–347
 - matched donors, 345
 - risk class approach, 344–345
 - hemoglobin F expression and severity of disease, 88
 - malaria natural selection effect on distribution, 153–154
 - management
 - iron chelation therapy
 - costs, 280–281
 - deferasirox, 279
 - deferiprone, 279–280
 - deferoxamine, 277–279
 - initiation, 275–276
 - monitoring, 275, 277, 280
 - principles, 271–272
 - mild phenotype prediction, 291–293
 - molecular diagnosis, 291
 - mutations
 - deletions
 - β -globin gene, 170, 172
 - classification, 170–171
 - upstream deletions, 172
 - dominantly inherited disease
 - alleles, 168–169
 - codon deletion or insertion, 174–175
 - elongated or truncated β -globin variants, 175
 - missense mutations, 173–174
 - nonsense mutation, 175
 - overview, 172–173
 - recessive versus dominant inheritance, 175–176
 - nondeletional forms
 - initiation codon of β -globin mutations, 169
 - point mutations, 162–166
 - posttranscriptional modification
 - mutants, 169
 - RNA processing mutants, 166–169
 - termination codon of β -globin mutations, 169–170
 - transcriptional mutants, 160–161, 166
 - normal HbA₂ β -thalassemia, 176

- overview, 159–160
- silent β -thalassemia, 176–177
- trans*-acting mutations, 177
- transposon induction, 177
- uniparental isodidomy, 178
- overview, 136–137
- pathophysiology, 201
- pluripotent stem cell modeling of disease, 376
- prevention programs
 - carrier detection, 288–290
 - education, 287–288
 - genetic counseling, 293
 - outcomes, 295–296
 - population control, 286–287
 - preimplantation diagnosis, 294–295
 - prenatal diagnosis, 293–295
 - prospects, 296
- β -Thalassemia intermedia
 - clinical morbidity and pathophysiology
 - endocrine dysfunction, 221
 - gallstone, 221
 - hypercoagulability and thromboembolism, 216–219
 - iron overload, 215–216
 - leg ulcer, 221
 - pseudotumors, 220–221
 - pulmonary hypertension, 219–220
 - genetic defects, 214–215
 - management
 - anticoagulation therapy, 223
 - hemoglobin F induction, 223
 - iron chelation, 222
 - red blood cell transfusion, 222
 - splenectomy, 222–223
 - overview, 213–214
- BMP6, osteonecrosis variants in sickle cell disease, 320
- Bohr, Christian, 2–3
- Bone marrow transplantation. *See* Hematopoietic stem cell transplantation
- Bone morphogenetic protein-6 (BMP-6), hepcidin synthesis regulation, 106–107
- C**
- CD163, hemoglobin scavenger system, 416–417
- Chronic granulomatous disease (CGD), gene therapy, 356–357, 363
- Cooley, Thomas, 4
- Coporphyrinogen, import by mitochondria, 119
- Coporphyrinogen oxidase (CPOX), heme synthesis, 119–120
- Corfu mutation, β -thalassemia, 176
- CREB-binding protein. *See* p300
- CTCF, globin gene expression regulation, 60
- Cytoglobin, comparative biology in vertebrates, 50–51
- D**
- Decitabine, sickle cell anemia management, 336
- Deferasirox
 - dosing, 276
 - pharmacology, 279
 - safety and tolerability, 279
- Deferiprone
 - advantages, 280
 - pharmacology, 279–280
 - safety and tolerability, 280
- Deferoxamine
 - advantages, 278
 - dosing, 276
 - pharmacology, 277–278
 - safety and tolerability, 278–279
- E**
- Embryonic stem cell (ESC)
 - banking of cells, 378–379
 - costs of therapy, 377–378
 - differentiation protocols, 376–377
 - disease modeling applications
 - hemoglobinopathies, 374–375
 - overview, 374
 - gene therapy, 377
 - pluripotency factors, 373–374
- EPO. *See* Erythropoietin
- EPP. *See* Erythropoietic protoporphyria
- Erythroblast-macrophage protein. *See* Macrophage-erythroblast attacher
- Erythroid Krüppel-like factor. *See* KLF1
- Erythropoiesis
 - erythroblastic islands and terminal differentiation, 21–22
 - hematopoietic system ontogeny, 13–17
 - hemoglobin E β -thalassemia and excess, 236
 - lineage differentiation
 - adult hematopoiesis, 18
 - ontogeny, 17–18
 - niche, 19–20
 - regulation, 19–21
 - transcriptional regulation, 22–24
- Erythropoietic protoporphyria (EPP)
 - ferrochelatase mutation, 125
 - overview, 125–127
 - pathophysiology, 122
- Erythropoietin (EPO)
 - anemia and underproduction, 38
 - central nervous system function, 33–34
 - erythrocytosis and overproduction, 38–39
 - erythropoiesis role, 20, 31
 - expression regulation
 - HNF-4, 37
 - hypoxia-inducible factor, 35–37
 - overview, 34–35

Index

- Erythropoietin (EPO) (*Continued*)
p300, 37–38
history of study, 29–30
ischemia/reperfusion injury studies, 34
production, 30–32
receptor interactions, 32–33
structure, 32
therapy, 39–41
- F**
- Fas, erythroid homeostasis role, 20, 22
FECH. *See* Ferrochelatase
Feline leukemia virus C receptor (FLVCR),
heme transport, 122
Ferritin, hemoglobin H disease levels, 250
Ferrochelatase (FECH)
erythropoietic protoporphyria mutation, 125
heme synthesis, 120–121
multienzyme complexes, 122–123
Fetal hemoglobin. *See* Hemoglobin F
FLVCR. *See* Feline leukemia virus C receptor
FOG-1
GATA mediation in hemoglobin gene expression
regulation, 69–72
NuRD interactions, 71, 75
FOP1, hemoglobin F induction studies, 95
- G**
- Gallstone
β-thalassemia intermedia, 221
hemoglobin E β-thalassemia, 236
Garrod, Archibald, 4
GATA1
β-thalassemia mutation, 177
globin gene expression regulation, 60
hemoglobin F induction studies, 91
hemoglobin gene expression regulation, 68–72
GATA2
erythropoiesis regulation, 22
GATA1 interactions, 70
Gene therapy, β-thalassemia
clinical trials, 361–363
erythroid cell models, 361
immunodeficiency disease management, 355–357
mouse models, 360–361
overview, 240, 355
selective amplification in vivo, 361
transduction optimization, 364–365
vectors
gammaretroviral vectors, 358–359
lentiviral vectors, 359–360
limitations, 356–357
locus control region, 358–359
retroviral vector modification for safety, 357–358
- Genome-wide association study (GWAS)
hemoglobin E β-thalassemia, 239
sickle cell anemia
overview, 316–317
population coverage, stratification,
and admixture, 317–318
published studies, 318–320
replication, 318
sequencing of variants, 318
statistical power, 317
stroke, 320
Graft-versus-host disease (GVHD), hematopoietic stem
cell transplantation, 344, 349–350
GVHD. *See* Graft-versus-host disease
GWAS. *See* Genome-wide association study
- H**
- Haptoglobin (Hp)
hemoglobin scavenger system, 415
therapeutic applications, 419
HbAE Bart's disease, 232
HbAEF Bart's disease, 232
HBOC. *See* Hemoglobin-based oxygen carrier
HBSIL, hemoglobin F induction studies, 94
HDAC. *See* Histone deacetylase
Heart rate variability (HRV), hemoglobin E
β-thalassemia, 235
Hematopoiesis. *See* Erythropoiesis
Hematopoietic stem cell (HSC), ontogeny and
development, 14–16
Hematopoietic stem cell transplantation (HSCT)
β-thalassemia
adults, 345
alternative donors, 345–346
mixed chimerism, 347
outcomes
haploidentical donors, 346–347
matched donors, 345
risk class approach, 344–345
sickle cell anemia
hemoglobin F increase after failed
transplantation, 350–351
mixed chimerism, 349–350
outcomes, 348–349
overview, 347–348
regimen modification, 350
- Heme
disorders
erythropoietic protoporphyria, 125–127
overview, 124–125
X-linked protoporphyria, 127
X-linked sideroblastic anemia, 127–128
low-density lipoprotein oxidation, 410
structure, 425
synthesis

- aminolevulinatase synthase, 116–117
- coporphyrinogen import by mitochondria, 119
- coporphyrinogen oxidase, 119–120
- ferrochelatase, 120–121
- hydroxymethylbilane synthase, 118
- multienzyme complexes, 122–124
- overview, 116
- porphobilinogen synthase, 117–118
- protoporphyrinogen oxidase, 120
- regulation, 121–122
- uroporphyrinogen decarboxylase, 118–119
- uroporphyrinogen synthase, 118
- Heme oxygenase-1 (HO-1)
 - hemoglobin scavenger system, 417
 - sickle cell anemia and malaria tolerance mechanism, 409
- Hemoglobin
 - comparative biology
 - gene clusters in jawed vertebrates
 - coordinated regulation between α -globin and β -globin gene clusters, 53
 - developmental regulation of expression, 51–53
 - evolution of multiple globin gene clusters, 53–54
 - lineage-specific gains and loss of β -like globin genes, 55–58
 - stability of α -globin gene cluster, 54–55
 - globin gene expression regulation, 58–61
 - globin heme protein family, 49–51
 - cooperativity, 388–390
 - developmental regulation of globin gene synthesis, 390–391
 - disorders. *See also specific disorders*
 - epistatic interactions, 154–155
 - frequency, 147–148
 - general classification, 134–135
 - natural selection for malaria protection
 - hemoglobin C, 151–152
 - hemoglobin E, 152–153
 - hemoglobin S, 148–151
 - thalassemia distribution impact, 153–154
 - fetal-to-adult hemoglobin switch. *See* Hemoglobin F
 - gene expression regulation
 - BCL11A, 68, 75–77
 - GATA, 68–75
 - KLF1, 76
 - overview, 67–68
 - history of study
 - diseases, 4–6
 - properties, 1–4
 - synthesis, 6–7
 - mean cell hemoglobin concentration and sickle cell anemia severity impact, 307
 - nitric oxide binding and disease modification, 411–413
 - oxidation and disease modification, 413–415
 - scavenger system
 - CD163, 416–417
 - haptoglobin, 415
 - heme oxygenase, 417
 - hemopexin, 415–416
 - therapeutic applications, 417–419
 - structure, 387–388
 - synthesis, 386–387
 - variants
 - definition, 383
 - globin chain elongation mutants, 396–397
 - high oxygen affinity variants, 393–395
 - identification, 390
 - laboratory testing, 391–392
 - low oxygen affinity variants, 395
 - methemoglobin variants, 395–396
 - multiple function variants, 397–399
 - table of types, 384–386
 - unstable variants, 392–393
- Hemoglobin A, comparative biology in vertebrates, 50–51
- Hemoglobin Bart's hydrops fetalis syndrome (BHFS)
 - overview, 137, 245, 251–252
 - prenatal management, 252–253
 - prevention, 252–253
- Hemoglobin-based oxygen carrier (HBOC)
 - oxidation, 415
 - pulmonary hemodynamic studies, 411, 413
 - sickle cell anemia treatment, 406–407
- Hemoglobin Bristol-Alesha, 399
- Hemoglobin C, natural selection for malaria protection, 151–152
- Hemoglobin Constant Spring (HbCS), 137, 249, 397
- Hemoglobin Cranston, 397
- Hemoglobin E
 - α -thalassemia interactions, 230–231
 - natural selection for malaria protection, 152–153
 - properties, 229–230
- Hemoglobin E β -thalassemia
 - clinical presentation, 200–201, 233–234
 - complications
 - cardiac disease, 235
 - endocrine dysfunction, 237
 - erythropoiesis excess, 236
 - gallstone, 236
 - hypertension, convulsions, and cerebral hemorrhage, 236
 - hypoxemia, 235–236
 - infection susceptibility, 235
 - iron overload, 236–237
 - jaundice, 236
 - splenomegaly, 234–235
 - thromboembolism, 236
 - genotype–phenotype correlation
 - α -thalassemia coinheritance, 238

Index

- Hemoglobin E β -thalassemia (*Continued*)
 anemia adaptation, 239
 β^E -globin mRNA splice variants, 238
 β -thalassemia mutations, 237–238
 genome-wide association study, 239
 hemoglobin F levels, 238
 pyrimidine 5' nucleotidase deficiency, 238
 severity, 237
 laboratory findings, 231, 234
 pathophysiology, 232–233
 prevention, 240
 treatment, 239–240
- Hemoglobin F
 expression
 regulation studies, 91–97
 severity of blood diseases, 88–89
 HbA₂ β -thalassemia levels, 176
 hematopoietic stem cell transplantation failure
 and increase, 350–351
 hemoglobin E β -thalassemia levels, 238
 hereditary persistence of fetal hemoglobin, 17–18,
 89, 136–137, 203
 induction therapy
 sickle cell anemia management, 336
 β -thalassemia intermedia, 223
 therapeutic application, 91–97
 sickle cell anemia severity impact, 88, 307
 β -thalassemia impact, 202–203
 therapeutic induction, 89–90
- Hemoglobin H α -thalassemia. *See* α -Thalassemia
- Hemoglobin S
 natural selection for malaria protection,
 148–151
 sickle cell anemia polymerization, 343–344, 399
- Hemoglobin Zurich, 397–398
- Hemopexin (Hpx)
 hemoglobin scavenger system, 415–416
 therapeutic applications, 419
- Hepcidin
 iron homeostasis, 106
 synthesis regulation
 erythropoiesis, 108
 inflammation, 109
 overview, 106–108
- Hereditary hemochromatosis, 109–110
- Hereditary persistence of fetal hemoglobin (HPFH),
 17–18, 89, 136–137, 203
- Herrick, James, 9
- HIF. *See* Hypoxia-inducible factor
- High-performance liquid chromatography (HPLC),
 hemoglobin variants, 391
- Histone deacetylase (HDAC), hemoglobin F induction
 with inhibitors, 90
- HMBS. *See* Hydroxymethylbilane synthase
- HNF-4, erythropoietin gene regulation, 37
- HO-1. *See* Heme oxygenase-1
- Hookworm, iron deficiency anemia association, 428–429
- HPFH. *See* Hereditary persistence of fetal hemoglobin
- HPLC. *See* High-performance liquid chromatography
- Hpx. *See* Hemopexin
- HRV. *See* Heart rate variability
- HSC. *See* Hematopoietic stem cell
- H SCT. *See* Hematopoietic stem cell transplantation
- Hydrogen peroxide, hemoglobin oxidation, 413
- Hydroxycarbamide, hemoglobin F induction for
 β -thalassemia intermedia, 223
- Hydroxymethylbilane synthase (HMBS)
 heme synthesis, 118
 multienzyme complexes, 123
- Hydroxyurea
 hemoglobin E β -thalassemia management, 240
 hemoglobin F induction, 90
 sickle cell anemia management, 335–336
- Hypoxemia, hemoglobin E β -thalassemia, 235–236
- Hypoxia-inducible factor (HIF)
 erythropoietin gene regulation, 35–37
 iron regulation, 106
 prolylhydroxylase inhibitors, 41
 VHL binding, 39
- I**
- Induced pluripotent stem cell (iPSC)
 banking of cells, 378–379
 costs of therapy, 377–378
 differentiation protocols, 376–377
 disease modeling applications
 hemoglobinopathies, 374–375
 overview, 374
 gene therapy, 377
 pluripotency factors, 373–374
- iPSC. *See* Induced pluripotent stem cell
- Iron
 accumulation rate in thalassemia, 272
 assessment
 cardiac concentration, 273–274
 extrahepatic iron, 274
 ferritin in serum, 272–273
 liver concentration, 273
 nontransferrin-bound iron, 274
 cellular iron
 functions, 103
 transport, 103–105
 uptake, 103
 disorders
 anemia of inflammation, 109
 deficiency, 109
 hereditary hemochromatosis, 109–110
 iron-refractory iron deficiency anemia, 109
 overload
 erythropoiesis inefficiency, 110
 transfusion, 109

- distribution and storage, 102
 - homeostasis
 - cellular, 104
 - systemic
 - hepcidin role, 106–109
 - overview, 102, 424
 - hypoxia sensing, 106
 - intake, 101–102
 - mitochondrial transport, 104–105
 - overload and β -thalassemia
 - β -thalassemia intermedia, 215–216
 - clinical manifestations
 - bone effects, 208
 - cardiac manifestations, 206–207
 - endocrine dysfunction, 207
 - hepatic manifestations, 207–208
 - tissue measurement, 206
 - hemoglobin E β -thalassemia, 236–237
 - pathophysiology, 204–206
 - treatment. *See* Iron chelation therapy
 - plasma concentration regulation, 102
 - proteins
 - classification, 423
 - synthesis regulation in erythroid cells, 105–106
 - recycling, 102
 - regulatory elements, 105
 - Iron chelation therapy
 - β -thalassemia intermedia, 222
 - costs, 280–281
 - deferasirox, 279
 - deferiprone, 279–280
 - deferoxamine, 277–279
 - initiation, 275–276
 - monitoring, 275, 277, 280
 - Iron deficiency anemia
 - clinical features, 425–427
 - diagnosis, 425–427
 - epidemiology, 425
 - etiology
 - blood loss, 427
 - diet, 429–430
 - hookworm, 428–429
 - malabsorption, 429–430
 - malaria comorbidity, 428
 - pregnancy and maternal deficiency, 427–428
 - overview, 109, 424–425
 - prospects for study, 431–432
 - refractory disease, 109
 - treatment and prevention
 - fortification, 430
 - umbilical cord delayed clamping, 430–431
- J**
- Jaundice, hemoglobin E β -thalassemia, 236
- K**
- KLF1
 - β -thalassemia mutation, 177
 - erythropoiesis regulation, 23–24
 - hemoglobin F induction studies, 91, 93–94, 96
 - hemoglobin gene expression regulation, 76
- L**
- LDL. *See* Low-density lipoprotein
 - Leg ulcer
 - β -thalassemia intermedia, 221
 - sickle cell anemia, 305
 - Low-density lipoprotein (LDL), oxidation
 - by heme, 410
- M**
- Macrophage-erythroblast attacher (MAEA), 21–22
 - MAEA. *See* Macrophage-erythroblast attacher
 - Magnetic resonance imaging (MRI)
 - angiography in β -thalassemia intermedia, 219
 - iron measurement in tissue, 206, 273–274
 - Malaria
 - hemoglobin natural selection for protection
 - hemoglobin C, 151–152
 - hemoglobin E, 152–153
 - hemoglobin S, 148–151
 - iron deficiency anemia comorbidity, 428
 - sickle cell anemia–induced tolerance
 - mechanisms, 409
 - MC. *See* Mixed chimerism
 - Mean cell hemoglobin concentration.
 - See* Hemoglobin
 - Med1, hemoglobin gene expression regulation, 72
 - Methemoglobin, variants, 395–396
 - Mitochondria
 - coporphyrinogen import, 119
 - iron transport, 104–105
 - Mixed chimerism (MC), hematopoietic stem cell transplantation, 347, 349–350
 - MRI. *See* Magnetic resonance imaging
 - MYB, hemoglobin F induction studies, 94, 96
 - Myoglobin
 - comparative biology in vertebrates, 50–51
 - polymorphisms and β -thalassemia impact, 203
- N**
- Ncx1, 17
 - Neuroglobin, comparative biology in vertebrates, 50–51
 - NF-E4, hemoglobin F induction studies, 95
 - Nitric oxide (NO), hemoglobin binding and disease modification, 411–413
 - NO. *See* Nitric oxide
 - NuRD, FOG-1 interactions, 71, 75

Index

O

- Osteoporosis, β -thalassemia, 208, 221
- Oxygen binding, hemoglobin variants
 - binding curve, 391
 - high oxygen affinity variants, 393–395
 - low oxygen affinity variants, 395

P

- p300
 - erythropoietin gene regulation, 37–38
 - GATA1 interactions, 71–72
- Pauling, Linus, 5
- PBGS. *See* Porphobilinogen synthase
- PCBPs. *See* Poly(RC)-binding proteins
- Perutz, Max, 3–5
- Pluripotent stem cell. *See* Embryonic stem cell; Induced pluripotent stem cell
- Poly(RC)-binding proteins (PCBPs), iron binding, 103–104
- Porphobilinogen synthase (PBGS), heme synthesis, 117–118
- PPOX. *See* Protoporphyrinogen oxidase
- Pregnancy
 - β -thalassemia intermedia considerations, 221
 - iron deficiency, 427–428
- Protoporphyrinogen oxidase (PPOX)
 - heme synthesis, 120
 - multienzyme complexes, 122–123
- PU.1, erythropoiesis regulation, 23
- Pulmonary hypertension, hemoglobin binding of nitric oxide, 411, 413
- Pulmonary hypertension, β -thalassemia intermedia, 219–220
- Pyrimidine 5' nucleotidase, hemoglobin E
 - β -thalassemia and deficiency, 238

R

- Red blood cell. *See* Erythropoiesis
- RUNX1, erythropoiesis regulation, 23

S

- SCA. *See* Sickle cell anemia
- SCE. *See* Stem cell factor
- SCID. *See* Severe combined immunodeficiency
- Severe combined immunodeficiency (SCID), gene therapy, 356–357
- Sickle cell anemia (SCA)
 - clinical features
 - adults, 306
 - early years, 303–304
 - first year, 303
 - late childhood, 304–305
 - overview, 306

- genome-wide association study
 - overview, 316–317
 - population coverage, stratification, and admixture, 317–318
 - published studies, 318–320
 - replication, 318
 - sequencing of variants, 318
 - statistical power, 317
 - stroke, 320
- genotype–phenotype correlations, 302–303
- geographic distribution and variability, 301–302, 308
- hematopoietic stem cell transplantation
 - hemoglobin F increase after failed transplantation, 350–351
 - mixed chimerism, 349–350
 - outcomes, 348–349
 - overview, 347–348
 - regimen modification, 350
- hemoglobin S polymerization, 343–344, 399
- heritability, 315–316
- history of study, 5–6, 9
- malaria tolerance mechanisms, 409
- management
 - acute chest syndrome, 331–332
 - acute splenic sequestration
 - adult care, 334
 - crisis, 331
 - decitabine, 336
 - education, 327–328
 - hemoglobin F induction, 336
 - hemoglobin-based oxygen carrier therapy, 406–407
 - hydroxyurea, 335–336
 - infection prevention and management, 328–329
 - pain control, 329–331
 - stroke management and screening, 332–334
 - transfusion, 334–335, 374–375
- mortality
 - causes, 308
 - infants, 326
 - survival rates, 306
- neonatal screening, 326–327
- overview, 138–139
- phenotype determination, 314–315
- pluripotent stem cell modeling of disease, 375–376
- prevention, 309
- severity determinants
 - α -thalassemia, 307
 - environment, 307–308
 - genetics, 308, 318–320
 - hemoglobin F levels, 88, 307
 - mean cell hemoglobin concentration, 307
- Sideroblastic anemia. *See* X-linked sideroblastic anemia
- SOX6, hemoglobin F induction studies, 92–93

- SOX8, α -thalassemia deletion, 191
- Splenectomy
- β -thalassemia intermedia management, 222–223
 - hemoglobin H disease management, 251
- Stem cell. *See* Embryonic stem cell; Hematopoietic stem cell transplantation; Induced pluripotent stem cell
- Stem cell factor (SCF), erythropoiesis role, 20
- Stroke
- β -thalassemia intermedia, 219
 - sickle cell anemia
 - genetic variants, 320
 - management and screening, 332–334
- T**
- TAL1
- GATA interactions, 73
 - globin gene expression regulation, 60
 - hemoglobin F induction studies, 91
- Thalassemia. *See also specific thalassemias*
- history of study, 5–9
 - molecular diagnosis, 291
 - prevention programs
 - genetic counseling, 293
 - population control, 286–287
 - preimplantation diagnosis, 294–295
 - prenatal diagnosis, 293–295
 - prospects, 296
- Thromboembolism
- β -thalassemia intermedia, 216–219
 - hemoglobin E β -thalassemia, 236
- Transferrin
- iron storage, 102
 - receptor, 103
- Transfusion
- animal studies of old blood transfusion, 407–409
 - β -thalassemia intermedia management, 222
 - hemoglobin E β -thalassemia management, 239–240
 - iron overload induction, 109
 - red blood cell storage lesion, 407
 - sickle cell anemia management, 334–335, 374
- U**
- UGT1A1*, sickle cell anemia variants, 320
- Umbilical cord, delayed clamping for iron deficiency anemia prevention, 430–431
- Uniparental isodidomy, β -thalassemia, 178
- UROD. *See* Uroporphyrinogen decarboxylase
- Uroporphyrinogen decarboxylase (UROD), heme synthesis, 118–119
- Uroporphyrinogen synthase (UROS)
- heme synthesis, 118
 - multienzyme complexes, 123
- UROS. *See* Uroporphyrinogen synthase
- V**
- VHL, hypoxia-inducible factor binding, 39
- X**
- X-linked protoporphyria (XLPP)
- ALAS-2 mutation, 127
 - overview, 127
 - pathophysiology, 122
- X-linked sideroblastic anemia (XLSA)
- ALAS-2 mutation, 124, 127–128
 - overview, 127–128
- XLPP. *See* X-linked protoporphyria
- XLSA. *See* X-linked sideroblastic anemia
- XMNI*, polymorphisms and β -thalassemia impact, 203
- XPD*, β -thalassemia mutation, 177